



Checkmate Pharmaceuticals Announces Data Presentations for Lead Program at The 34th Annual Meeting of The Society for Immunotherapy of Cancer

CAMBRIDGE, Mass., November 1, 2019 – Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced two oral presentations at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC).

On Friday, November 8, 2019 at 12:15pm ET, Dr. John M. Kirkwood, professor of medicine, dermatology, and clinical and translational science at the University of Pittsburgh School of Medicine and the Clinical and Translational Science Institute at the University of Pittsburgh, will present late-breaking data from a Checkmate Sponsored Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy.

Title: Durable responses in anti-PD-1 refractory melanoma following intra-tumoral injection of a Toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab

Abstract #: 11548/O87

On Saturday, November 9, 2019 at 6:15pm ET, Dr. Diwakar Davar, an assistant professor of medicine at the University of Pittsburgh School of Medicine, will present data from his investigator-sponsored trial evaluating neoadjuvant treatment with CMP-001 in combination with nivolumab in Stage IIIB/C/D Melanoma.

Title: Phase II Trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high risk resectable melanoma (MEL): Preliminary Results

Abstract #: 11648/O34

About CMP-001

CMP-001 is a first-in-class CpG-A Toll-like receptor 9 (TLR9) agonist that is encapsulated in a virus-like particle. CMP-001 is designed to induce both innate and adaptive anti-tumor immune responses, thereby converting immunologically “cold” tumors into immunologically “hot” tumors, with the potential to mediate tumor regression. It is the only CpG-A class TLR9 agonist in clinical trials and differs from other CpG classes in clinical development by having a native DNA backbone that induces the highest levels of type I Interferon (IFN). Based on analyses of gene expression in human tumors showing that increased IFN and related immune gene expression is associated with better response to PD-1 inhibition, it is believed that this mechanism of action may restore, enable or improve responses to anti-PD-1/PD-L1 therapeutics. CMP-001 is being evaluated in multiple tumor types to assess safety, activity, alternative routes of administration and combination with other immunotherapies and modalities. For information on CMP-001 trials that are currently recruiting patients, please visit www.clinicaltrials.gov.

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate's lead product candidate, CMP-001, is an investigational cancer immunotherapeutic that has been shown to reverse resistance to PD-1 therapy in some patients. Checkmate is a privately held company headquartered in Cambridge, MA. Additional information regarding Checkmate is available at www.checkmatepharma.com.

###

CONTACT:

Karen Sharma

MacDougall

781-235-3060

ksharma@macbiocom.com